G protein-coupled receptor kinase 2 (GRK2), as a vital Ser/Thr kinase, is an important regulatory protein in the inflammatory immune response (IIR) by maintaining the balance between the function of inflammatory immune cells and non-conventional inflammatory immune cells and regulating inflammatory immune cell infiltration, inflammatory cytokine secretion, and the signaling associated with endothelial function. However, the imbalance of GRK2 expression and activity plays an important role in the development of IIR-related diseases, such as hypertension, heart failure, Alzheimer's disease, type 2 diabetes mellitus, insulin resistance, rheumatoid arthritis, thyroid cancer, multiple sclerosis, and liver cancer. Small molecule GRK2 inhibitors, including balanol, Takeda inhibitors, paroxetine and derivatives, M119 and gallein, peptides, RNA aptamers, Raf kinase inhibitory protein, and microRNAs, that can directly inhibit GRK2 kinase activity have been identified by different strategies. This review discusses recent progress in one of the hallmark molecular abnormalities of GRK2 in IIR-related diseases and explores the soft regulation of IIR by innovative drugs reducing the excessive activity of GRK2 to basal levels, without damaging normal physiological function, to ameliorate inflammatory disorders.
Introduction
The inflammatory immune response (IIR) is a physiological or excessive systemic response induced by inflammatory immune cells based on the variation of internal and external environments [1] . A physiological IIR protects the body from pathological damage caused by changes to internal and external environments. However, an excessive 
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Regulatory role of GRK2 in IIR-related diseases
Cardiovascular system: Hypertension and HF Hypertension is a multifaceted disease characterized by elevated systemic blood pressure as a consequence of increased peripheral resistance, which is the most important risk factor preceding the development of other cardiovascular diseases [24] . Low-grade inflammation has been recognized as a crucial pathogenic factor in hypertension and cardiovascular diseases [25] . Previous studies have shown that the inflammatory mechanisms of hypertension include the up-regulation of cytokine expression, such as soluble intercellular adhesion molecule-1 (ICAM-1), IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-α, IFN-γ and chemoattractant factors, and the down-regulation of nitric oxide (NO), vascular endothelial growth factor, and reactive oxygen species [26, 27] .
GRK2 is overexpressed in the vascular tissue and lymphocytes of patients with hypertension ( Table 2 ). GRK2 overexpression can inhibit AKT, shift the vascular tone toward constriction, and decrease eNOS activity, leading to endothelial dysfunction [28] . NO, as a vasodilating factor, is important in hypertension and the immune system. NO is synthesized by the endothelium to oppose the vasoconstriction induced by the sympathetic nervous system. NO has also been associated with an increase in leukocyte adhesion to mesenteric venules and an increase of monocyte/macrophage infiltration, which lead to the development of hypertension [29] . Therefore, the down-regulation of GRK2 in hypertension can increase eNOS activity and reduce high blood pressure to normal levels [30] .
HF is the end stage of many underlying cardiovascular diseases, and it still has a poor prognosis despite considerable progress in pharmacological treatment and new interventional and surgical therapeutic options [31] . Previous studies have shown that HF is no longer considered as a pure cardiac entity; it involves several inflammatory pathways and immune regulation and later detrimental neurohumoral compensatory mechanisms [32] . The GPCR/TLR/IL-1 signaling pathway plays a crucial role in the regulation of cardiac function, which can result in the activation of the NF-κB system and the production of chemokines, inflammatory cytokines, and catecholamine [33] . Inflammatory cytokines, such as TNF-α, IFN-γ, IL-6, and IL-1β, can accelerate myocardial hypertrophy and fibrosis and down-modulate cardiac function during the development of HF [34] . Chemokines, including CXCL8 and CCL2, are thought to indirectly damage and cause dysfunction of cardiac muscle through the activation and production of reactive oxygen species, matrix metalloproteinases, and inflammatory cytokines. 
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Response GRK2 is overexpressed in HF (Table 2) . Increased cardiac GRK2 expression can promote the phosphorylation of β-AR, leading to β-AR desensitization and internalization, which play a pivotal role in inducing HF-related dysfunction [4] . Recently, it has been shown that GRK2 protein levels are markedly increased by the activation of TLR2 in macrophages. TLR2 can regulate CXCL8-stimulated CXCR2 expression by up-regulating the expression of GRK2 in circulating neutrophils [21] . Therefore, down-regulating GRK2 expression may be an important therapeutic strategy for HF by regulating the cardiac β-AR and CXCR2 signaling pathway.
Nervous system: Alzheimer's disease Alzheimer's disease (AD) is one of the most prevalent and devastating dementing disorders, and it is characterized by the gradual loss of neurons from specific regions of the central nervous system, synaptic degeneration, accumulation of senile plaques and neurofibrillary tangles in association cortices, and an inflammatory response to amyloid-β, which can increase the adhesion of activated microglia, inflammasomes, astrocytes, and leukocytes to post-capillary venules [35] . The clinical features of AD include amnesic-type memory impairment, language deterioration, visuospatial deficits, metabolic and oxidative stress damage, and impaired cerebral perfusion. Some potential peripheral inflammatory biomarkers of AD, as neuroinflammatory triggers, can promote the activation of the peripheral immune system, including adhesion proteins, such as P-selectin, MCP-1, platelet endothelial cell adhesion molecule-1, and ICAM-1 and -2, secreted inflammatory mediators (chemokines and interleukins), and platelets contain important enzymes involved in inflammatory intermediary synthesis such as phospholipase A2 and cyclooxygenase-2 [36] . TLR4 inflammatory mediator signaling plays a pivotal role in the pathogenesis of AD, as it may be involved in AD inflammatory responses through the up-regulation of certain cytokines, such as IL-1β, IL-10, IL-17, and TNF-α [37] . GPCRs can mediate the actions of messengers of key modulators of cardiac and vascular cell function, and they are related to the neurovisceral damage and vascular complications of AD.
GRK2 is a cytosolic protein that contributes to the adaptation of GPCR/TLR4 inflammatory mediator signaling, and it regulates downstream signaling through these receptors [38] . GRK2 mRNA and protein expression are higher in patients with AD than in normal controls, and the up-regulation of GRK2 levels in peripheral lymphocytes of patients with AD includes two aspects. First, there is a moderate decrease of membrane content and a drastic increase of cytosolic content. Second, the total levels of GRK2 are also significantly up-regulated. GRK2 protein concentrations are related to the degree of cognitive impairment [39] . A previous study showed that the suppression of GRK2 translocation to the membrane can regulate TLR4 signaling-mediated monocyte migration, which may reveal a novel function for TLR4 signaling in promoting the migration of innate immune cells. GRK2 is involved in cardiac and vascular GPCR desensitization and the dysfunction of GPCR coupling in patients with AD. The data show an imbalance in the activity of NOS isoforms, ET-1, and oxidative stress, which can lead to an inadequacy in the antioxidant response capacity to abate sufficiently metabolic and oxidative insults in patients with AD. GRK2 plays a role in these deleterious processes. Thus, GRK2 might be utilized as a novel biomarker in the diagnosis and clinical monitoring of AD (Table 2) .
Endocrine system: type 2 diabetes mellitus Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, vascular endothelial dysfunction, and increased blood glucose levels. It can accelerate atherosclerosis and hypertension, leading to increased risks of cardiovascular morbidity and mortality [40, 41] . Macrophages and lymphocytes, as unexpected promoters and controllers of adipose tissue biology and glucose homeostasis, are important in the promotion of inflammation associated with insulin resistance and T2DM [42] . M1 macrophages can impair insulin receptor signaling in peripheral tissues by secreting TNF-α and IFN-γ, while M2 macrophages can maintain insulin sensitivity by secreting IL-10. The infiltration of B cells into adipose tissue appears to be key to the establishment of adipositis 
Response and insulin resistance, and it can promote insulin resistance by enhancing local macrophage TNF-α production. Therefore, TNF-α is highly expressed in adipose tissue of obese animals and humans, in which it can mediate insulin resistance. Insulin suppresses hepatic glucose production and regulates glucose uptake in muscle and fat through the translocation of GLUT4 to the cell surface [43] . GRK2 is overexpressed in obese animals and humans, and a 50% down-regulation of GRK2 levels in hemizygous GRK2 +/-mice is sufficient to protect against TNF-induced alterations in glucose homeostasis and insulin signaling, which provides strong evidence for a key role for GRK2 in the modulation of insulin sensitivity in physiological and pathological conditions [44] . GRK2 directly phosphorylates insulin receptor substrate-1, causing insulindependent negative signaling feedback, including inhibition of the membrane translocation of GLUT4. Previous studies have found that the activation of the AKT/eNOS pathway is impaired in the aorta of diabetic patients, resulting in endothelial dysfunction. GRK2 recognizes and phosphorylates agonist-activated GPCRs and plays a crucial role in signal transduction pathways to modulate intracellular effectors, such as endothelial function in diabetic mice, which exerts this effect by ameliorating AKT/eNOS dysfunction [45] (Table 2) .
Cancer: thyroid carcinoma
Thyroid carcinoma (TC) is the most common endocrine malignant tumor, which originates from both follicular and parafollicular cells. TC is classified as a well-differentiated carcinoma, including papillary carcinoma and follicular carcinoma, and an undifferentiated or anaplastic carcinoma [46] . Lymphocytic infiltration results from the local recurrent activation and proliferation of circulating leukocytes and plays a key role in the initiation and development of TC [47] . Cells migrate from the circulation into tissues following the release of cytokines, such as TNF-α, IL-lβ, and IFN-γ, and up-regulate the expression of adhesion molecules, such as ICAM-1, vascular cell adhesion molecule 1, and E-selectin, on endothelial cells. The up-regulation of ICAM-1 expression may play an important role in thyroid tumors and they may interact with the immune system and have a cytotoxic effect [48] .
The thyroid stimulating hormone (TSH) receptor is a seven-transmembrane domain receptor belonging to the GPCR family. The effect of TSH on GRK2 expression was mimicked by forskolin, which can activate adenylyl cyclase (AC) and increase cAMP levels. Studies have shown that compared with their adjacent normal tissues, GRK2 expression is increased in TC, including papillary, follicular, and anaplastic types, because TSH, insulin, and insulin-like growth factor-I are involved in the progression of TC. GRK2 overexpression can promote the proliferation of TC cell lines. The reduction of cell proliferation by GRK2 revealed a new role for this kinase in the growth of TC. The mechanism may involve the reduction of lymphocytic infiltration and the down-regulation of cytokines and adhesion molecules, such as TNF-α, IL-lβ, IFN-γ, and ICAM-1 [49] (Table 2) .
Immune system disease: rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by the inflammation of joint tissue and synovial hyperplasia with the proliferation of fibroblast-like synoviocytes (FLS), which eventually leads to cartilage and bone destruction. The synovial environment in RA is comprised of a complex mix of cell types including T and B cells, neutrophils, monocytes/macrophages, and FLS. It has been shown that the activation of autoreactive T and B cells stimulates macrophages to produce pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [50, 51] . FLS, as synovial fibroblasts or type B synoviocytes, are the predominant cell type comprising the structure of the synovial intima and the most common cell type in the pannus-cartilage junction, and contribute to joint destruction through their production of cytokines, chemokines, and matrix-degrading molecules by migrating to and invading joint cartilage in RA [52] . Prostaglandin E2, an important inflammatory cytokine, is increased in FLS. It regulates a broad range of physiological processes in the immune system as well as the cardiovascular, endocrine, and neural systems. It also produces a response to pro-inflammatory cytokines, which in turn negatively regulates IL-17 and TNF-α expression and the TNF/IL-1-induced activation of FLS through EP2/EP4 receptors, and results in the modulation of pro-inflammatory cascades. The NF-κB pathway, one of the major signaling pathways in FLS, plays a pivotal role in joint inflammation. NF-κB is highly activated in the synovial tissue of patients with RA and in collagen-induced arthritis (CIA) mice [53, 54] . NF-κB regulates the expression of various pro-inflammatory mediators,
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including cytokines, such as TNF-α, IL-1β, and IL-6, chemokines, and cellular adhesion molecules. NF-κB activation in FLS also contributes to the pathogenesis of RA by activating the transcription of matrix metalloproteinases, which are responsible for the invasive properties of FLS [55, 56] . GRK2 expression is increased in the synovium of CIA rats during inflammation [57] . GRK2 overexpression can regulate the EP receptor, leading to EP receptor desensitization, a decrease of cAMP levels, and the proliferation of FLS (unpublished). GRK2 is associated with an increase of NF-κB transcriptional activity and up-regulation of NF-κB activity, leading to the production of inflammatory cytokines, enhancement of inflammatory cell infiltration, and damage to cartilage and bone [58] ( Table 2) .
Development of GRK2 inhibitors
GRK2, which is 689 amino acids (aa) in length, has three domains: an N-terminal domain, kinase domain, and C-terminal domain. The structural features of GRK2 have played a vital role in the development of GRK2 inhibitors. Its C-terminal domain contains approximately 54 aa (618-671 aa) and has three important regions: the NLT includes the HF motif and interacts with the β-helix, C-helix, and β4 strand of the N lobe; the active-site tether (AST) serves as a gate for ATP and substrate binding and peptide substrate recruitment; and the CLT interacts with the E-helix of the C lobe and with the αC-β4 loop, β8 strand, and the interlobe linker spans the N and C lobes [59] . The kinase domain of GRK2 (185-513 aa), as an ATP binding site, contains various α-helixes and β-turns (Fig. 1) . The Gβγ binding sites are located at 1-53 aa and 643-670 aa; the Gαq binding sites are located at 20-185 aa. GRK2 also contain small lobes (186-272 aa and 496-513 aa), hinge region (273-275 aa), large lobe (276-495 aa), P-loop (191-201 aa), activation loop (containing Ser334), and αB-αC-helix (224-248 aa), which form important binding sites for GRK2 inhibitors to regions that are GRK2 "allosteric sites" [60] .
GRK2, as a relevant modulator of inflammatory responses, can interact with various signal transduction proteins related to the chemokine-induced migration of T cells and monocytes, such as MEK, AKT, PI3Kγ, and GIT. GRK2 expression and function is altered in several inflammatory conditions and has emerged as an important protein in the onset or progression of IIR-related diseases. Therefore, GRK2 is a new drug target for the treatment of some diseases. At present, GRK2 inhibitors include balanol, Takeda inhibitors, paroxetine and derivatives, M119 and gallein, peptides, RNA aptamers, RKIP, and microRNAs (miRNAs), which have different structures, inhibition effects, and inhibition mechanisms (Table 3) .
Small molecule GRK2 inhibitors
Balanol Balanol, as an ATP mimetic, is a metabolite synthetized by the fungus Verticillium balanoides, and it functions as a competitive inhibitor of ATP at the kinase domain of GRK2 [61] . The X-ray crystal structures of balanol and balanol analogs bound to PKA revealed that the compound binds to a conformation of PKA, which forms an intermediate state to the "open" (inactive) and "closed" (active) states of the kinase. Balanol exhibits some selectivity among GRK subfamilies, and it seems to recognize and stabilize a unique inactive conformation of GRK2. Cocrystallization of balanol-GRK2 complexes indicated that balanol binding to GRK2 can lead to conformational changes of GRK2 in the P-loop and in the αB-αC loop of the small lobe. Analysis of the binding sites of balanol and GRK2 showed that Gly201, Val205, Lys220, Glu239, Met274, Asp272, Ala321, Leu324, and Asp335 of GRK2 may bind to balanol by hydrogen bonding (Table 4A) .
Paroxetine
Paroxetine is a selective serotonin reuptake inhibitor anti-depressant drug that can specifically bind to the kinase domain of GRK2 as an off-target with a binding affinity in the micromolar range and selectively inhibits GRK2 kinase activity [62] . Paroxetine stabilizes the kinase domain of GRK2 in a conformation that could serve as a unique platform for the development of GRK2-specific inhibitors, which is distinct from the other classes of currently known GRK2 inhibitors as well as from other protein kinase A, G, and C family members.
Structural analysis of the GRK2-paroxetine complex indicated that the drug occupies the P-loop (191-201 aa) and the AST (474-492 aa) [63, 64] . Paroxetine may bind to GRK2 by hydrogen bonding with Arg199, Gly200, Val205, Asp278, and Leu324, and the complex forms specific hydrogen bonds to the backbone atoms of Asp272, Met274, and Ala321 (Table 4B) .
Derivatives of paroxetine
GSK180736A, a derivative of paroxetine, is structurally similar to paroxetine and was developed as a Rho-associated coiled-coil kinase 1 inhibitor. Cocrystal structures of GSK180736A and GRK2 showed that GSK180736A co-crystallized in the active site, and it 
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Response was identified as an inhibitor of GRK2 [65] . Analysis of the binding sites of GSK180736A and GRK2 showed that Arg199, Gly200, Val205, and Leu324 of GRK2 may bind to GSK180736A by hydrogen bonding, and Arg199 in the P-loop and van der Waals interactions with residues in the large lobe; the compound makes specific hydrogen bonds to the backbone atoms of Asp272, Met274, and Ala321 (Table 4C) .
Takeda inhibitors
Takeda inhibitors (CMPD101 and CMPD103A), as heterocyclic compounds, exhibit higher selectivity and show more therapeutic potential for GRK2 than does balanol. They were discovered by the Takeda Pharmaceutical Company Ltd. CMPD101 and CMPD103A inhibit GRK2 by inducing a slight closure of the kinase domain of GRK2, because they bind to GRK2 in an open, non-catalytic conformation [66] . Crystal structures of Takeda inhibitorbound GRK2 showed that they bind to the active sites of GRK2 including the large lobe, P-loop, and αB-αC-loop, and GRK2 subfamily-specific residues in the P-loop and αB-αC-loop regions could contribute to the selectivity of these compounds for GRK2. Gly200, Phe202, Val205, Lys220, and Leu324 of GRK2 may form hydrogen bonds with CMPD101 (Table 4D) , and Ile197. Gly200, Phe202, Val205, Lys220, Leu324, Asp335, and Leu338 of GRK2 may form hydrogen bonds with CMPD103A (Table 4E) . Fig. 1 . The structural and functional feature of GRK2 domain GRK2 contains N-terminal region (green), kinases domain (purple) and C-terminal domain (blue). The KD of GRK2 with ~ 328aa has some important α-helix and β-turn. It contains the small lobe (186-272aa, 496-513aa), hinge region (273-275aa), the large lobe (276-495aa), the P-loop (191-201aa), the activation loop (contains Ser334), αB-αC-helix (224-248aa), which form the important GRK2 inhibitors binding to regions that GRK2 "allosteric site". The C-terminal domain of GRK2 with ~ 54aa has the N-lobe tether (NLT), the active-site tether (AST), the C-lobe tether (CLT).
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M119 and galleon M119 and its highly homologous structure, gallein, demonstrated the ability to reduce GRK2 recruitment to the membrane of cardiomyocytes induced by iso treatment by enhancing β-AR signaling in vitro, and have a high apparent affinity for Gβγ [67] . Thus, they were used to inhibit Gβγ-GRK2 interactions and selected as lead drugs to define structure-activity requirements for binding to Gβγ. M119 and gallein can both terminate the progression of HF and improve cardiac function, morphometry, histology, and gene expression in animal models of either new onset or established HF.
Other GRK2 inhibitors RNA aptamers. C13, as an RNA aptamer, can selectively inhibit GRK2 with high affinity. It can stabilize a unique inactive conformation of GRK2 through multiple interactions leading to the inhibition of GRK2 [68] . Both within and outside the kinase domain active site pocket, the terminal stem of the aptamer indirectly contributes to its selectivity by constraining a selected portion of the RNA. The RNA sequence of C13.18 is CCAUACGGGAGAGAAACU, and it Table 4 . Poseview image and the hydrogen bond of GRK2
• inhibitors
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Response inhibits GRK2 at the nanomolar level (IC50 = 220 ± 40 nM). Studies indicated that the C13.18 aptamer binds to the αF-αG loop and αG helix of GRK2 (391-410 aa; PDB entry 2BCJ) [69] . Kaposi's sarcoma-associated herpes virus (KSHV) is linked with Kaposi's sarcoma and lymphomas and encodes 12 precursor miRNAs within its latency-associated region, which are processed into at least 25 mature miRNAs named KSHV-miR-K12-1~12 (or simply as miR-K1~12). Of the 12 viral KSHV-encoded miRNAs that function as regulators by maintaining viral latency and inhibiting viral lytic replication, the expression of miR-K3 in latent KSHV-infected cells can suppress both viral lytic replication and gene expression. miR-K3-targeted GRK2 can promote the migration and invasion of endothelial cells by inducing CXCR2 expression and activating AKT signaling, which was initially identified as a Ser/ Thr kinase implicated in the regulation of GPCRs with arrestins and the modulation of cell motility by the complex [70] .
Peptides. GRK2ct (β-ARKct) peptide, as a GRK2 inhibitor, was first designed based on the knowledge that the main function of the GRK2ct peptide, the C-terminal fragment of GRK2, is to inhibit endogenous GRK2 by translocating to the plasma membrane and binding Gβγ. GRK2ct peptide is approximately 200 aa in length [71] .
The catalytic fragment (383-390 KLLRGHSP) of GRK2 is composed by the last part of the α-helix F (residues 383-386) and the first part of the α strand (residues 387-390) within the HJ loop. Several crystallographic and mutational studies have reported that HJ-αG residues are involved in substrate binding and in binding to upstream activators [72, 73] . A GRK2-specific peptide inhibitor (GRK-Inh) was derived from the first intracellular loop of hamster β2-AR and has a peptide sequence of MAKFERLQTVTNYFITSE. Studies have confirmed the cardioprotective effect of GRK-Inh by increasing the activation of the MAPK signaling pathway, which oversees the processes of cell growth and proliferation. Thus, treatment with GRK-Inh can prevent cardiomyocyte apoptosis and the consequent impairment of heart function [74] .
RKIP. RKIP, as a multifaceted kinase modulator, belongs to an evolutionarily conserved family of phosphatidylethanolamine-binding proteins. It can control vital intracellular signaling pathways, including the signaling cascades of Raf/MEK/ERK, NF-κB, glycogen synthase kinase-3, and GPCRs. Raf-1 controls the proliferation and differentiation of different cell types by phosphorylating and activating ERK1 [75] . The enhanced dimerization of RKIP translates into decreased Raf-1 levels and increased GRK2 inhibition. Ach can induce RKIP phosphorylation, promote the association of RKIP and GRK2, decrease the association of RKIP and Raf-1, and stimulate ERK1/2 activity. Phosphorylation by PKC also switches the association of RKIP from Raf-1 to GRK2, leading to the inhibition of GRK2 activity [76] .
Conclusion
GRK2 is a regulator of immune cell function, inflammatory factor secretion, and related signaling pathways. Studies have shown that GRK2 is highly expressed in different types of immune cells, and it can attenuate the chemokine-induced migration of T cells and monocytes as a relevant modulator of inflammation [77] . GRK2 phosphorylates chemotactic GPCRs, such as CCR5, CCR2b, CXCR4, and CXCR2, and chemotactic receptors for substance P, S1P or formyl-peptide, and can also modify PDGF or EGF plasma membrane tyrosine kinase receptors, cytoskeleton proteins (ezrin and tubulin), p38MAPK, and metabotropic glutamate receptors, which contribute to leukocyte trafficking to inflammatory foci, T cell egression from lymphoid organs, and leukocyte activation or proliferation [78] . GRK2 can reduce lymphocytic infiltrates, and down-regulate the production of cytokines and adhesion molecules, such as TNF-α, IL-lβ, IFN-γ, and ICAM-1. NF-κB regulates the expression of various pro-inflammatory mediators, including cytokines, such as TNF-α, IL-1β, and IL-6, chemokines, and cellular adhesion molecules. GRK2 expression is increased in the synovium, which can activate NF-κB in FLS, leading to the production of inflammatory cytokines. Thus, GRK2 is up-regulated in IIR-related diseases, including hypertension, HF, AD, T2DM, RA, and TC.
Interestingly, GRK2 protein expression and kinase activity are down-regulated in leukocytes of patients with active relapsing-remitting multiple sclerosis (MS) or with secondary progressive MS [79] . MS is a chronic inflammatory disease of the central nervous system, and the pathogenesis of MS involves the infiltration of activated T lymphocytes and macrophages into the brain and spinal cord. Previous data demonstrated that a 50% decrease of GRK2 expression in T cells from GRK2 +/-mice results in an increased chemotactic response to the chemokines CCL3, CCL4, and CCL5 via the CCR5-mediated signaling pathway [19] . Reduced cellular levels of GRK2 can increase not only the response to chemokines but also to multiple GPCRs, including β-AR. These chemokines can also increase ERK, protein kinase B, and calcium levels. Studies have demonstrated that GRK2 overexpression has an inhibitory role in the growth of hepatoma carcinoma cells [80] . Dominant-negative GRK2-K220R or a GRK2-specific peptide inhibitor increases tumor mass. The activity of the MAPK signaling pathway can promote tumor growth, while GRK2 overexpression can suppress MAPK activation and nuclear translocation, GRK2 inhibitors enhance the MAPK pathway, induce nuclear ERK1/2 targets, notably the proto-oncogene FOS, and promote tumor growth [81] .
These data clearly implicate the functional importance of "normal" GRK2 levels for the body (Fig. 2) . The dynamic equilibrium of GRK2 expression and activity also plays an important role in the development of IIR-related drugs. The development of IIR-related innovative drugs targeting GRK2 should pay attention to controlling the excessive activity of GRK2 to the basal level, and not damage normal physiological function, and to ameliorate inflammatory disorders. Our group first put forward and clearly defined the new concept of "soft regulation of inflammatory immune responses (SRIIR)", and SRIIR, as a new field of IIR-related innovative drug development, places an emphasis on controlling the excessive activity of IIR-related cells and not to impair normal physiological function. At present, the conventional IIR drugs in the clinical setting, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs (glucocorticoid hormones), immunosuppressive medicine (chemical medicine, biological medicine, and Chinese natural medicine) in the treatment of IIR-related diseases, have a good curative effect in treating IIR-related diseases, but result in serious adverse reactions in the liver, kidney, gastrointestinal tract, respiratory, blood, and cardiovascular systems, bone marrow, and nervous system. SRIIR drugs do not completely suppress the functions of cells or gene and protein expression and activity, but selectively control excessive activity to basal levels to restore the dynamic balance of cells, which can better exert the treatment effects of drugs and minimize the occurrence of adverse reactions. GRK2 may regulate IIR by reducing the infiltration of inflammatory cells and the release of inflammatory cytokines, which play a vital role in treating IIR-related diseases. Thus, GRK2, as a definitive example for the development of SRIIR-related innovative drugs, is becoming a new target for the treatment of IIR-related diseases. 
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